{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:25:26Z","timestamp":1794349526273,"version":"4.9.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["2008-4246"],"award-info":[{"award-number":["2008-4246"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eclinm.2025.103605","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:11:58Z","timestamp":1761855118000},"page":"103605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Adaptive designs in randomized clinical trials: reanalysis of the HOVON87\/NMSG18 multiple myeloma trial"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-0354","authenticated-orcid":false,"given":"Maarten R.","family":"Seefat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek G.","family":"van der Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Nasserinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronno","family":"van der Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9072-1220","authenticated-orcid":false,"given":"Anders","family":"Waage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf-Henrik","family":"Mellqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette Juul","family":"Vangsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna J.T.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Febe","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula F.","family":"Ypma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5846-0531","authenticated-orcid":false,"given":"Hedwig M.","family":"Blommestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-5464","authenticated-orcid":false,"given":"David G.J.","family":"Cucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurjen","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.eclinm.2025.103605_bib1","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials","volume":"125","author":"Hariton","year":"2018","journal-title":"BJOG"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103605_bib2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/jnci\/djs141","article-title":"Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer","volume":"104","author":"Gan","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103605_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103605_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-024-01037-3","article-title":"Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial","volume":"14","author":"van der Maas","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103605_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103605_bib6","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103605_bib7","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103605_bib8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103605_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1745-6215-9-46","article-title":"Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: a survey from the Italian National Monitoring Centre for Clinical Trials","volume":"9","author":"Floriani","year":"2008","journal-title":"Trials"},{"issue":"28","key":"10.1016\/j.eclinm.2025.103605_bib10","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1002\/sim.4102","article-title":"Adaptive increase in sample size when interim results are promising: a practical guide with examples","volume":"30","author":"Mehta","year":"2011","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103605_bib11","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1186\/s13063-020-04931-w","article-title":"A systematic review of the \"promising zone\" design","volume":"21","author":"Edwards","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.eclinm.2025.103605_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1745-6215-15-61","article-title":"An investigation of the impact of futility analysis in publicly funded trials","volume":"15","author":"Sully","year":"2014","journal-title":"Trials"},{"issue":"15","key":"10.1016\/j.eclinm.2025.103605_bib13","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/jama.2021.10174","article-title":"Interim analyses during group sequential clinical trials","volume":"326","author":"Meurer","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103605_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/2231-4040.191414","article-title":"Interim analysis: a rational approach of decision making in clinical trial","volume":"7","author":"Kumar","year":"2016","journal-title":"J Adv Pharm Technol Res"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103605_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1740774511399128","article-title":"The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease","volume":"8","author":"Pritchett","year":"2011","journal-title":"Clin Trials"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103605_bib16","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103605_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jama.2019.9346","article-title":"Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial","volume":"322","author":"Johnston","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103605_bib18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/10543406.2014.901341","article-title":"Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses","volume":"24","author":"Chen","year":"2014","journal-title":"J Biopharm Stat"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103605_bib19","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/sim.2151","article-title":"A review of methods for futility stopping based on conditional power","volume":"24","author":"Lachin","year":"2005","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103605_bib20","article-title":"Recent innovations in adaptive trial designs: a review of design opportunities in translational research","volume":"7","author":"Kaizer","year":"2023","journal-title":"J Clin Transl Sci"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103605_bib21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.annonc.2023.06.002","article-title":"ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0","volume":"34","author":"Kiesewetter","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103605_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11899-019-0495-9","article-title":"Should overall survival remain an endpoint for multiple myeloma trials?","volume":"14","author":"Holstein","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103605_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.2024025421","article-title":"MRD accelerating myeloma drug development","volume":"144","author":"Costa","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103605_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103605_bib26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40265-023-01879-4","article-title":"Results from expanded access programs: a review of academic literature","volume":"83","author":"Polak","year":"2023","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103605_bib27","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jamaoncol.2024.3466","article-title":"Externally controlled studies using real-world data in patients with hematological cancers: a systematic review","volume":"10","author":"Hermans","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:42:02Z","timestamp":1794346922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025005395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":26,"alternative-id":["S2589537025005395"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103605","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adaptive designs in randomized clinical trials: reanalysis of the HOVON87\/NMSG18 multiple myeloma trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103605"}}